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Abstract 
To determine the influence of buthionine sulfoximine (BSO) on boron 
biodistribution after sulfhydryl borane (BSH) administration for boron neutron capture 
therapy, the effectiveness of the combination of BSO with sulfhydril- (BSH) and 
non-sulfhydril (B12H12, BNH3) boron compounds, and the interval between BSO and 
BSH administration, the retention of boron in tissues have been evaluated using a 9L rat 
tumor model. Simultaneous administration of BSH and BSO showed significantly 
higher boron accumulation compared to that without BSO, however there was no 
difference in tissue boron level between B12H12 and BNH3 administration with BSO or 
without BSO. The longer interval (6 h) between BSH and BSO administration related to 
the highest boron concentration in the brain and subcutaneous tumors compared to 
shorter intervals (0.5, 3 h). Boron concentration in subcutaneous and brain tumor was 
maintained 6 and 12 h after the administration of BSH following BSO pretreatment.  
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1. Introduction 
The success of boron neutron capture therapy (BNCT) highly depends on the 
selective and sufficient accumulation of 10B atoms in tumor cells to achieve at least 10 - 
30 μg / g of 10B in tumor tissue and high tumor/brain and tumor/blood ratios of boron 
concentration. There are only two boron delivery agents available for clinical BNCT 
trials for malignant glioma: 10B-enriched boronophenyl alanine (BPA) and sulfhydryl 
borane (BSH). Of these, BSH passively distributes through the disrupted blood-brain 
barrier (BBB) from blood to tumor tissues. The boron concentration in the normal brain 
with an intact BBB remains minimal, whereas the tumor 10B concentration is related to 
both the tumor vessel density and the serum 10B level. Tumor-to-blood boron 
concentration ratios ranging from 0.5 to 1.0 have been reported in human patients 
treated with BSH-mediated BNCT (Yamamoto et al, 2013).  
To determine the influence of BSO on boron biodistribution after BSH 
administration, the differences between the combination of BSO with sulfhydril- (BSH) 
and non-sulfhydril (B12H12, BNH3) boron compounds, the interval between BSO and 
BSH administration, and the retention of boron in the normal brain, brain tumor, 
subcutaneous tumor and other normal organs have been evaluated.  
 
2. Materials and methods 
Reagents used or vended were BSH (Katchem, Prague, Czech Republic), 
buthionine sulfpximine (BSO), pentobarbital sodium (Kyoritsu Seiyaku, Japan) and 
tribromoethanol (Sigma-Aldrich, MO, USA), isoflurane (Escain, Mylan, Osaka, Japan), 
and standard boron solution (Wako Pure Chemicals, Tokyo, Japan). The boron 
compounds without sulfhydryl group, B12H12 and B12H11NH2-Na2 (BNH3) were kindly 
provided by Prof. Nakamura from Gakushuin University, Tokyo, Japan. 
All protocols of animal experiments were pre-approved by the Animal 
Experiment Ethic Committee of the University of Tsukuba and conducted following the 
‘‘Regulations for Animal Experiments”. The preparation of 9L glioma cells for the 
subcutaneous tumor and the brain tumor model was described in our previous work 
(Yoshida et al., 2008).  Briefly, rat gliosarcoma cell line (9 L) was maintained in Earl’s 
minimal essential medium (MEM, Sigma-Aldrich, MO, USA) supplemented with 10% 
fetal bovine serum (JRH Nitirei Bioscience, Japan) and 1% penicillin-streptomycin 
(Sigma-Aldrich, MO, USA). To determine the tissue boron concentration, 7-week-old 
male Fisher (F344) rats, weighing ca. 150 g, were used.  2 × 106 of 9L cells were 
subcutaneously inoculated in the right leg, and 1x105 of the cells were simultaneously 
injected in the rat brain. When the flank tumor grew up to 10 mm in diameter, BSO (5 
mmol/kg in phosphate buffer saline i.p.) and boron compound containing sulfhydryl 
group (BSH) or boron compounds without sulfhydryl group (B12H12 or BNH3) in PBS 
at a dose of 100 mg/kg each were administered via tail vein.  
To compare the efficacy of boron compounds with/without the sulfhydryl 
group, the animals were sacrificed 3 h after the administration of boron reagents (n= 5). 
In other group, BSH was injected 0, 0.5, 3, and 6 h after the administration of BSO, and 
the animals were sacrificed at 3, 6 and 12 hours after the administration of boron 
reagents (n= 5). Blood, liver, kidney, muscle, subcutaneous tumor, brain and brain 
tumor samples were obtained and analyzed for boron concentration using inductively 
coupled plasma-atomic emission spectroscopy (ICP-AES) (ICPS-8100, Shimadzu, 
Tokyo, Japan). The data were statistically analyzed by the paired t-test using JMP 
statistical software (ver.10, SAS, Marlow, UK) and difference in comparison was 
regarded as significant with p < 0.05. 
 
3. Results 
Simultaneous administration of BSH and BSO showed significantly higher 
boron concentration compared to that without BSO. There was no difference in tissue 
boron levels between BSO-pretreatment (BSO+) and no-BSO (BSO –) groups after 
B12H12 or BNH3 administration (Table 1).   
The longer interval (6 h) between BSH and BSO administration related to the 
highest boron concentration in the brain and subcutaneous tumor, compared to the 
shorter intervals (0.5, 3 h) (Fig.1). The boron concentration in subcutaneous tumor with 
the 6 h interval between BSO and BSH injection was significantly higher compared to 
that after 0.5 and 0 h intervals (p = 0.007 and 0.007, respectively). Moreover, the boron 
concentration in the brain tumor with the 6 h interval was significantly higher compared 
to that with 0, 0.5, and 3 h intervals (p= 0.003, 0.0045, and 0.0356, respectively).  
The boron concentration in blood, kidney, liver and subcutaneous tumor 
samples was maintained 6 and 12 h after administration of BSH following BSO 
pretreatment (6 h interval) (Fig. 2). The blood boron concentration using BSO 
pretreatment was up to 20 times higher at 6 h (47.6 μg/ml) and 12 h (55.7 μg/ml) 
compared to that without BSO, leading to the retention of boron level in the liver, 
kidney, subcutaneous tumor and brain tumor.  
 
4. Discussion 
Buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis, depletes 
intracellular sulfhydryl-conjugates such as glutathione (GSH) by inhibiting its 
biosynthetic enzyme c-glutamylcysteine synthetase (Griffith and Meister, 1979). We 
previously reported that BSH, a boron-containing sulfhydryl-conjugate, shows higher in 
vitro and in vivo boron uptake in tumor cells by simultaneous administration with BSO, 
leading to the improvement of tumor control probability (Yoshida 2004, 2008). In the 
previously used Fisher-344 rat subcutaneous tumor model, boron accumulation in 
subcutaneous tumor, blood, skin, muscle, liver, and kidney was significantly enhanced 
after administration of BSH (100 mg/kg) with BSO (5 mmol/kg) and maintained for 12 
h, and the in vivo tumor growth was significantly delayed by BSH-BSO-mediated 
BNCT (Yoshida 2004, 2008). However, it is still unclear whether such enhancement 
effect is caused by the sulfhydryl group of BSH, and if it is similar in brain and brain 
tumors which the intact BBB. Metabolic transformation of one or more BSH 
metabolites, such as BSH sulfenic acid (BSOH), BSH sulfinic acid (BSO(2)H), BSH 
disulfide (BSSB), BSH thiosulfinate (BSOSB),and BSH–S-cysteine conjugate (BSH–
CYS) (Gibson et al, 2001) can be affected by GSH depletion, or directly influenced by 
BSO. In this study, simultaneous administration of BSH and BSO showed significantly 
higher boron concentration compared to that without BSO. There was no difference in 
tissue boron level between BSO-pretreatment and no-BSO groups after B12H12 or 
BNH3 administration.    
We suggest that time-dependent increase in tumor boron concentration might 
be related to the increasing level of redox regulating agents in tumor tissue, though, 
under limited conditions of this study, high boron level in subcutaneous and brain tumor 
samples could be associated with the retention of boron in the blood. Thus, higher boron 
concentration after BSO-pretreatment might have a potential risk of normal tissue 
damage by BNCT. Further evaluation should be focused on more ideal intervals 
between BSO and BSH administration and the timing of neutron irradiation. 
Hypervascular extraaxial tumor, such as meningioma, might be a candidate for this 
treatment method. 
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Table 1 
 BSH B12H12 BNH3 
 BSO+ BSO- BSO+ BSO- BSO+ BSO- 
Subcutaneous  
tumor 
26.3± 4.3 5.0± 2.9 3.1± 0.6 2.5± 0.3 2.8± 0.8 2.4 ± 0.4 
Blood 55.2±15.0 8.1± 6.2 6.9± 1.1 6.0± 1.0 5.8± 0.9 5.5± 1.0 
Brain 2.6± 1.4 0.6± 0.7 0.5± 0.05 0.5 ± 0.1 0.6± 0.2 0.5 ± 0.2 
Skin 34.2± 9.8 6.3± 4.3 4.8 ± 1.1 4.0 ± 0.5 2.5 ± 1.6 3.0± 1.1 
Muscle 7.4 ± 2.8 1.2± 0.9 1.5 ± 0.2 1.3 ± 0.3 1.1 ± 0.2 1.0 ± 0.2 
Liver 71.4± 22.6 12.6±8.1 5.2 ± 0.3 4.6 ± 0.4 3.1 ± 1.2 2.4 ± 0.5 
Kidney 82.3± 28.5 31.6±15.9 10.6± 1.0 9.6± 1.5 4.4± 2.1 4.4± 1.3 
 
 
Fig. 1  
 
Fig. 2 
 
 
* * 
Figure and table legend  
Table 1:  Boron concentration in samples (µg/g) after administration of sulfhydril- 
(BSH) and non-sulfhydril- (B12H12 and BNH3) boron compounds. Each sulfhydril- or 
non-sulfhydril-boron compound was administrated with BSO simultaneously. All 
samples were collected 3 h after the compound administration. Data shown as means ± 
SDs. 
 
Fig.1 Boron concentration in samples (µg/g) depending of the interval (h) between BSO 
and BSH administration.*p < 0.05 
 
Fig.2 Retention of 10B in the tissues (boron concentration, µg/g) 6 and 12 h following 
BSH administration with/without BSO. 
 
 
 
